| Description | Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser[1][2]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Membrane Transporter/Ion Channel >>P-glycoprotein |
|---|
| In Vitro | Epoxylathyrol has no significant antiproliferative activity in EPG85-257P (parental; IC50>100 uM), EPG85-257RNOV (multidrug resistance [MDR] phenotype; IC50>100 uM), and EPG85-257RDB (multidrug resistance [MDR] phenotype; IC50=70.53 uM)[1]. |
|---|
| References | [1]. Mariana Alves Reis, et al. Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer. Front Pharmacol. 2020 May 8;11:599. [2]. Wei Jiao, et al. Lathyrane diterpenes from Euphorbia lathyris as modulators of multidrug resistance and their crystal structures. Bioorg Med Chem. 2009 Jul 1;17(13):4786-92. |
|---|
| Epoxylathyrol |
| Spiro[9H-cyclopenta[a]cyclopropa[f]cycloundecene-9,2'-oxiran]-4(1H)-one, 1a,4a,5,6,7,7a,8,10,11,11a-decahydro-4a,7,8-trihydroxy-1,1,3,6-tetramethyl-, (1aR,2Z,4aR,6S,7S,7aR,8S,9R,11aS)- |
| Spiro[9H-cyclopenta[a]cyclopropa[f]cycloundecene-9,2'-oxiran]-4(1H)-one, 1a,4a,5,6,7,7a,8,10,11,11a-decahydro-4a,7,8-trihydroxy-1,1,3,6-tetramethyl-, (1aR,2E,4aR,6S,7S,7aR,8S,9R,11aS)- |
| (1aR,2Z,4aR,6S,7S,7aR,8S,9R,11aS)-4a,7,8-Trihydroxy-1,1,3,6-tetramethyl-1a,4a,5,6,7,7a,8,10,11,11a-decahydrospiro[cyclopenta[a]cyclopropa[f][11]annulene-9,2'-oxiran]-4(1H)-one |
| (1aR,2E,4aR,6S,7S,7aR,8S,9R,11aS)-4a,7,8-Trihydroxy-1,1,3,6-tetramethyl-1a,4a,5,6,7,7a,8,10,11,11a-decahydrospiro[cyclopenta[a]cyclopropa[f][11]annulene-9,2'-oxiran]-4(1H)-one |